Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FT536

Cell therapy (NK cells) · Kills target cells, directed at MICA and MICB · developed by Fate Therapeutics

Phase 1 Most advanced trial
FATE Developer
1 Registered trials

What is FT536?

FT536 is an allogeneic, off-the-shelf natural killer cell therapy derived from a clonal induced pluripotent stem cell line and engineered to express a chimeric antigen receptor targeting the alpha 3 domain of MICA and MICB, a high-affinity non-cleavable CD16 receptor, and an IL-15/IL-15 receptor alpha fusion, with CD38 knocked out. It kills MICA/B-expressing tumor cells and is studied in astrocytoma and glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (NK cells)
Targets
MICA (antigen), MICB (antigen)
Mechanism
Kills target cells, directed at MICA and MICB
Pathways
NKG2D signaling, cytokine and chemokine secretion
Therapy area
Oncology
Developer
Fate Therapeutics (FATE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07560865 Phase 1 Astrocytoma Recruiting FATE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AstrocytomaGlioblastomaProgressive Disease

Other drugs acting on MICA / MICB

More from Fate Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.

Follow FATE, the company behind FT536

See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FATE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.